Ditchcarbon
  • Customers
  1. Organizations
  2. Eli Lilly and Company
Public Profile
Pharmaceutical Preparation Manufacturing
GB
updated 15 days ago

Eli Lilly and Company

Company website

Eli Lilly and Company, commonly referred to as Lilly, is a global leader in the pharmaceutical industry, headquartered in the United Kingdom. Founded in 1876, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative solutions in diabetes, oncology, immunology, and neuroscience. Lilly is renowned for its pioneering products, such as insulin therapies and cancer treatments, which are distinguished by their commitment to research and development. The company has achieved significant milestones, including the introduction of groundbreaking medications that have transformed patient care. With a robust market position, Eli Lilly continues to be recognised for its contributions to healthcare, consistently ranking among the top pharmaceutical companies worldwide.

DitchCarbon Score

How does Eli Lilly and Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

63

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

49

Industry Benchmark

Eli Lilly and Company's score of 63 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.

80%

Let us know if this data was useful to you

Eli Lilly and Company's reported carbon emissions

In 2023, Eli Lilly and Company reported total greenhouse gas emissions of approximately 5,134,500,000 kg CO2e, with emissions distributed across various scopes: 182,000,000 kg CO2e (Scope 1), 345,000,000 kg CO2e (Scope 2), and 5,013,500,000 kg CO2e (Scope 3). The company has made significant strides in reducing its carbon footprint, achieving a 26% absolute reduction in emissions from 2020 to 2023, despite business growth during this period. Eli Lilly has set ambitious climate commitments, including a legally binding target to reach net zero emissions in the UK by 2050 for both Scope 1 and Scope 2 emissions. Additionally, the company aims to be carbon neutral in its own operations (Scope 1 and 2) by 2030. These commitments reflect a proactive approach to climate action, aligning with industry standards and expectations. The company’s emissions data is not cascaded from any parent organization, indicating that these figures are independently reported. Eli Lilly's ongoing efforts to enhance emissions reporting across its full value chain further demonstrate its commitment to sustainability and transparency in addressing climate change.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2007201020112012201320142015201620192020202120222023
Scope 1
527,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
1,310,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
14,000,000
00,000,000
00,000,000
-
-
-
-
-
000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Eli Lilly and Company's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Eli Lilly and Company is in GB, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Eli Lilly and Company is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Schering-Plough Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated about 9 hours ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated about 9 hours ago

MERCK Kommanditgesellschaft auf Aktien

DE
•
Pharmaceutical Preparation Manufacturing
Updated about 9 hours ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 9 hours ago

Novartis Pharmaceuticals Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated about 9 hours ago

Hikal

IN
•
Pharmaceutical Preparation Manufacturing
Updated about 9 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250725.9
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy